SCHEDULE 13G/A: Kynam Capital Management Discloses 4.99% Stake in Dynavax Technologies

Kynam Capital Management, LP, along with its general partner and managing member, Yue Tang, has disclosed a beneficial ownership of 4.99% in Dynavax Technologies Corp. common stock as of December 31, 2024.

Summary

• Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang collectively reported beneficial ownership of 6,560,835 shares of Dynavax Technologies Corp. common stock.
• This aggregate amount represents 4.99% of the outstanding common stock of Dynavax Technologies Corp.
• The reporting persons hold shared voting power and shared dispositive power over all 6,560,835 shares.
• The filing is an Amendment No. 1 to Schedule 13G, indicating a change from a previous filing or an initial filing below the 5% threshold.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently be positive or negative for the company's operations or financial performance. It is neutral in sentiment.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm, indicating a significant but non-controlling stake in a biotechnology company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake in the company, which can be relevant for understanding the shareholder base and potential influence, though this stake is below the 5% threshold for a 13D filing which implies intent to influence.

Key Dates

Keywords

Dynavax Technologies Corp, Kynam Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Yue Tang